drugset
drugset / Trial / NCT06424665

A Study of FZ-AD005 in Patients With Advanced Solid Tumors

NCT06424665 ↗

Phase 1 Recruiting 162 enrolled Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.
NaSingle-groupOpen-labelTreatment

Summary

A First-in-Human, Open Label, Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of FZ-AD005 in Patients with Advanced Solid Tumors.

Timeline

Start
2024-07-03
Primary completion
2026-08-01
Completion
2027-12-01

Drugs

EvaluationDrugModalityDoseRoute
Subject FZ-AD005 Other / unclassified — Intravenous

Indications

neoplasm